Panzyga
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Panzyga
- Generic name
- IMMUNE GLOBULIN INTRAVENOUS (HUMAN)
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- e2cc5ddf-119e-ade3-79c2-c712cfbee099
- SPL ID
- fb008bad-3696-e7b9-d3f8-3718e16e19d8
- Version
- 10
- Effective date
- 2025-05-08
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:02:30
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125587 | derived:openfda.application_number |
| application number | BLA125587 | openfda.application_number | |
| brand name | Panzyga | openfda.brand_name | |
| generic name | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) | openfda.generic_name | |
| manufacturer name | Pfizer Laboratories Div Pfizer Inc | openfda.manufacturer_name | |
| ndc | package | 0069-1415-02 | openfda.package_ndc |
| ndc | package | 0069-1224-01 | openfda.package_ndc |
| ndc | package | 0069-1312-01 | openfda.package_ndc |
| ndc | package | 0069-1224-02 | openfda.package_ndc |
| ndc | package | 0069-1011-01 | openfda.package_ndc |
| ndc | package | 0069-1312-02 | openfda.package_ndc |
| ndc | package | 0069-1011-02 | openfda.package_ndc |
| ndc | package | 0069-1558-01 | openfda.package_ndc |
| ndc | package | 0069-1558-02 | openfda.package_ndc |
| ndc | package | 0069-1415-01 | openfda.package_ndc |
| ndc | package | 0069-1109-02 | openfda.package_ndc |
| ndc | package | 0069-1109-01 | openfda.package_ndc |
| ndc | product | 0069-1415 | openfda.product_ndc |
| ndc | product | 0069-1109 | openfda.product_ndc |
| ndc | product | 0069-1312 | openfda.product_ndc |
| ndc | product | 0069-1011 | openfda.product_ndc |
| ndc | product | 0069-1558 | openfda.product_ndc |
| ndc | product | 0069-1224 | openfda.product_ndc |
| ndc11 | package | 00069110901 | derived:openfda.package_ndc |
| ndc11 | package | 00069155802 | derived:openfda.package_ndc |
| ndc11 | package | 00069141501 | derived:openfda.package_ndc |
| ndc11 | package | 00069101102 | derived:openfda.package_ndc |
| ndc11 | package | 00069155801 | derived:openfda.package_ndc |
| ndc11 | package | 00069122402 | derived:openfda.package_ndc |
| ndc11 | package | 00069131201 | derived:openfda.package_ndc |
| ndc11 | package | 00069141502 | derived:openfda.package_ndc |
| ndc11 | package | 00069101101 | derived:openfda.package_ndc |
| ndc11 | package | 00069122401 | derived:openfda.package_ndc |
| ndc11 | package | 00069131202 | derived:openfda.package_ndc |
| ndc11 | package | 00069110902 | derived:openfda.package_ndc |
| rxcui | 2102455 | openfda.rxcui | |
| rxcui | 2102435 | openfda.rxcui | |
| rxcui | 2102472 | openfda.rxcui | |
| rxcui | 2102463 | openfda.rxcui | |
| rxcui | 2102469 | openfda.rxcui |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. (See WARNING and PRECAUTIONS [ 5.4 ], PATIENT COUNSELING INFORMATION [ 17 ]) Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV product containing sucrose. PANZYGA does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. (See DOSAGE and ADMINISTRATION [ 2.3 ], WARNINGS and PRECAUTIONS [ 5.2 , 5.4 ]) WARNING: THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE See full prescribing information for complete boxed warning - Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. - Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose. -For patients at risk of thrombosis, renal dysfunction, or renal failure, administer PANZYGA at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions to PANZYGA. Epinephrine should be available immediately to treat any severe acute hypersensitivity reactions ( 5.1 ). Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure ( 5.2 ). Hyperproteinemia, increased serum osmolarity and hyponatremia may occur in patients receiving PANZYGA ( 5.3 ). Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to PANZYGA treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia ( 5.6 ). Aseptic Meningitis Syndrome may occur in patients receiving PANZYGA, especially with high doses or rapid infusion ( 5.5 ). Monitor patients for pulmonary adverse reactions [transfusion-related acute lung injury (TRALI)] ( 5.7 ). PANZYGA is made from human plasma and may contain infectious agents, e.g., viruses, variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease agent ( 5.10 ). 5.1 Hypersensitivity Severe hypersensitivity reactions may occur (See Contraindications ( 4 )) . [ 1 ] In case of hypersensitivity, discontinue PANZYGA infusion immediately and institute appropriate treatment. Have epinephrine available for immediate treatment of severe acute hypersensitivity reactions. PANZYGA contains trace amounts of IgA (average 100 µg/mL in a 10% solution). IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactoid reactions when administered PANZYGA (See Contraindications ( 4 )) . 5.2 Renal Failure Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur upon use of PANZYGA in predisposed patients. Ensure that patients are not volume depleted prior to the initiation of the infusion of PANZYGA. For patients at risk of renal dysfunction because of pre-existing renal insufficiency or predisposition to acute renal failure (such as individuals with diabetes mellitus, age greater than 65 years, volume depletion, sepsis, paraproteinemia, or those receiving known nephrotoxic drugs), administer PANZYGA at the minimum infusion rate practicable (See Boxed Warning, and Dosage and Administration ( 2 )). Periodic monitoring of renal function tests and urine output is particularly important in patients judged to be at risk of developing acute renal failure. Assess renal function, including a measurement of blood urea nitrogen (BUN)/serum creatinine, prior to the initial infusion of PANZYGA and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation of the product. 5.3 Hyperproteinemia, Increased Serum Viscosity and Hyponatremia Hyperproteinemia, increased serum viscosity and hyponatremia may occur in patients receiving PANZYGA therapy. It is clinically critical to distinguish true hyponatremia from pseudohyponatremia related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity and a higher risk of thromboembolic events.[ 2 ] 5.4 Thrombotic Events Thrombosis may occur following treatment with immune globulin products, including PANZYGA. Risk factors include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia / markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombotic events, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.[ 3-5 ] (See BOXED WARNING, DOSAGE and ADMINSTRATION [ 2 ], PATIENT COUNSELING INFORMATION [ 17 ]) 5.5 Aseptic Meningitis Syndrome Aseptic meningitis syndrome (AMS) may occur with PANZYGA treatment. Discontinuation of treatment has resulted in remission of AMS within several days without sequelae. The syndrome usually begins within several hours to two days following infusion with PANZYGA. It is characterized by symptoms and signs including severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting. Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dl, but negative culture results. Conduct a thorough neurological examination in patients exhibiting such symptoms and signs, including CSF studies, to rule out other causes of meningitis. Patients with a history of migraine may be more susceptible.[ 6 ] AMS may occur more frequently following high doses (≥ 2 g/kg) and/or rapid infusion of IGIV. 5.6 Hemolysis PANZYGA may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin test (DAT) (Coombs’ test) result and hemolysis. Delayed hemolytic anemia can develop subsequent to IGIV therapy due to enhanced RBC sequestration and acute hemolysis, consistent with intravascular hemolysis, has been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV. The following risk factors may be associated with the development of hemolysis following IGIV administration: high doses (e.g., 2 g/kg or more), given either as a single administration or divided over several days, and non-O blood group.[ 7 ] Other individual patient factors, such as an underlying inflammatory state (as may be reflected by, for example, elevated C-reactive protein or erythrocyte sedimentation rate), have been hypothesized to increase the risk of hemolysis following administration of IGIV [ 8 ], but their role is uncertain. Hemolysis has been reported following administration of IGIV for a variety of indications, including ITP. Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors noted above. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit prior to infusion and within approximately 36 to 96 hours post-infusion. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform confirmatory laboratory testing, including direct antiglobulin test. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating on-going hemolysis. 5.7 Transfusion-Related Acute Lung Injury (TRALI) Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)] may occur in patients administered IGIV.[ 9 ] TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Signs and symptoms typically appear within 1 to 6 hours after transfusion. Patients with TRALI may be managed using oxygen therapy with adequate ventilatory support. Monitor recipients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-HLA and anti-neutrophil antibodies in both the product and patient’s serum. 5.8 Hypertension Elevations of systolic blood pressure to 180 mm Hg or more and/or of diastolic blood pressure to more than 120 mm Hg (hypertensive urgency) can be observed during and/or shortly following infusion of IGIV. Such elevations are reported more often among patients with a history of hypertension. Check patients for a history of hypertension and current antihypertensive medication use. Monitor blood pressure prior to, during, and following PANZYGA infusion. 5.9 Volume Overload Carefully consider the relative risks and benefits before prescribing the high dose regimen (for chronic ITP) in patients at increased risk of volume overload. 5.10 Transmission of Infectious Agents Because PANZYGA is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the variant Creutzfeldt-Jakob disease and Creutzfeldt-Jakob disease (CJD) agent. The risk of infectious agent transmission has been reduced by screening plasma donors and by including virus inactivation/removal steps in the manufacturing process of PANZYGA. Report all infections thought by a physician or other healthcare provider to have been possibly transmitted by this product to Pfizer Inc. at 1-800-438-1985. Discuss the risks and benefits of PANZYGA with the patient before prescribing or administering this product. 5.11 Monitoring Laboratory Tests After infusion of immunoglobulin, the transitory rise of the passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test. Clinically assess patients with known renal dysfunction, diabetes mellitus, age greater than 65 years, volume depletion, sepsis, paraproteinemia, or those receiving nephrotic agents, and monitor as appropriate (BUN; serum creatinine, urine output) during therapy with PANZYGA. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with polycythemia, cryoglobulins, fasting chylomicronemia/markedly high triglycerides, or monoclonal gammopathies. Consider measuring hemoglobin or hematocrit at baseline and approximately 36 to 96 hours post-infusion in patients at higher risk of hemolysis. If signs and/or symptoms of hemolysis are present after an infusion of PANZYGA, perform appropriate laboratory testing for confirmation. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient’s serum.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS PI: The most common adverse reactions observed at a rate of more than 5% in subjects in clinical trials were: headache, abdominal pain, fever, nausea, and fatigue. Chronic ITP in adults: The most common adverse reactions observed at a rate of more than 5% in subjects in clinical trials were: headache, fever, nausea, vomiting, dizziness, and anemia. CIDP in adults: The most common adverse reactions observed at a rate of more than 5% in subjects in clinical trials were: headache, fever, dermatitis and blood pressure increased. The most serious adverse reaction observed with PANZYGA treatment during clinical trials was aseptic meningitis in one subject. PI - The most common adverse reactions reported in greater than 5% of subjects during a clinical trial were: headache, nausea, fever, fatigue, and abdominal pain ( 6 ). Chronic ITP in adults - The most common adverse reactions reported in greater than 5% of subjects during a clinical trial were: headache, fever, nausea, vomiting, dizziness, and anemia ( 6 ). CIDP in adults – The most common adverse reactions reported in greater than 5% of subjects during a clinical trial were: headache, fever, dermatitis, blood pressure increased ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a product cannot be directly compared to rates in the clinical trials of another product and may not reflect the rates observed in clinical practice. Treatment of Primary Humoral Immunodeficiency (PI) In a prospective, open-label, single-arm, multicenter study in 51 children and adults with PI, subjects received PANZYGA at a dose between 200 to 800 mg/kg body weight every 3 or 4 weeks. Subjects participated in the study for a mean of 360 days. Infusions were initiated at a rate of 1 mg/kg/minute for the first 30 minutes, and, if tolerated, could be advanced to a maximum tolerated rate not exceeding 8 mg/kg/minute. The mean age of subjects was 26.8 years (range: 2 to 65 years). This study was followed by an extension study that evaluated the safety of PANZYGA administered at higher infusion rates in 21 subjects that successfully had completed the first study. Nineteen of the 21 enrolled patients received PANZYGA up to the maximum allowed infusion rate of 14 mg/kg/minute. In the extension study, medication-related adverse events were reported in 4 of 21 subjects (19%). Adverse reactions occurring in more than 5% of subjects were nausea (9.5%) and headache (9.5%). In the study in PI, infusion-related adverse events (during or within 72 hours after the end of infusion) were reported in 16 patients (76%) enrolled in the 3-weeks treatment schedule and in 22 patients (73%) in the 4-weeks treatment schedule. Overall, 38 infusions (5%) had at least one adverse event considered related to study medication: 5 infusions (3%) in children, 4 infusions in adolescents (2%), and 29 infusions (8%) in adults. Study medication-related (possible or probable) infusion-related adverse reactions were associated with 35 infusions (5%) (overall); study medication-related headache was noted in 21 infusions (3%). Table 1: Adverse Reactions* Occurring in more than 5% of Subjects with PI Adverse Reaction No. of Subjects with Adverse Reaction(percentage of subjects) Headache 11 (22%) Abdominal pain (upper) 7 (14%) Fever 7 (14%) Nausea 5 (10%) Sinusitis 4 (8%) Fatigue 3 (6%) Bronchitis 3 (6%) * Any infusional and any study medication related adverse events. Treatment of Chronic Immune Thrombocytopenia (ITP) in Adults In a prospective, open-label, single-arm, multicenter study, 40 adult subjects with chronic ITP received PANZYGA at a dose of 2 g/kg, administered daily as 1 g/kg intravenous infusions on 2 consecutive days. 3/40 subjects did not receive a second infusion of PANZYGA due to infusion reactions, including chills, headache, fever and nausea. All subjects except 1 received at least 1 infusion with the highest rate of 8 mg/kg/minute. Pre-medication to alleviate potential adverse drug reactions was not allowed in the study. There were 67 treatment emergent adverse events (TEAEs) reported in 24 (60%) subjects that were related to administration of PANZYGA. 55 of these adverse events ( 82%) were infusional adverse events that occurred within 72 hours after start of the infusion. Seven of these adverse events in 2 subjects were severe. These included headache, nausea, vomiting and chills. When analyzed by infusion, infusion-related adverse events were reported in 33 of the 77 infusions (43%). Table 2: Adverse Reactions* Occurring in more than 5% of Subjects with Chronic ITP in Adults Adverse Reaction No. of Subjects with Adverse Reaction(percentage of subjects) Headache 20 (50%) Fever 9 (23%) Nausea 7 (18%) Vomiting 4 (10%) Dizziness 4 (10%) Anemia 4(10%) * Any infusional and any study medication related adverse events. One out of 40 subjects with ITP treated with PANZYGA developed aseptic meningitis on Day 2 of the infusion. This subject was managed with antibiotics and supportive care with recovery. Baseline direct Coomb’s test was performed in 39/40 subjects that were treated with PANZYGA. 10/39 (26%) subjects subsequently developed positive Coomb’s test. One subject was not tested at baseline but had positive results on all 3 subsequent visits. Four of these subjects (10%) developed hemolytic anemia after receiving PANZYGA. These resolved spontaneously without any intervention. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy in Adults In a prospective, double-blind, randomized, multicenter study, 142 adult subjects with CIDP aged between 18 and 83 years were enrolled and randomized 1:2:1 to receive first a loading dose of 2 g/kg and then 0.5 g/kg, 1.0 g/kg or 2.0 g/kg PANZYGA for 7 maintenance infusions at 3-week intervals during the 24-week Dose-evaluation Phase (mean doses administered - including loading and rescue doses - were 0.91, 1.24 and 1.97 g/kg for 0.5, 1 and 2g/kg group, respectively). All 142 subjects in this study received at least 1 dose of PANZYGA. The median maximum infusion rate was 0.12 mL/kg/min throughout the study in all dose groups. Seventy-three out of the 142 subjects experienced a total of 209 adverse reactions (AR). Table 3 summarizes the most frequent ARs that occurred in more than 5% of subjects. Generally, the incidence of ARs was similar across the dose groups; the only AR where a dose effect was evident was headache, with an incidence of 2.9% in the 0.5 g/kg group, 14.5% in the 1.0 g/kg group and 23.7% in the 2.0 g/kg group. Pre-medication for AEs was only allowed in subjects who had adverse events during 2 consecutive infusions. During the study 11 subjects (7.75%) received premedication. Table 3: Adverse Reactions* Occurring in more than 5% of Adult Subjects with CIDP Adverse Reaction No. of Subjects with Adverse Reaction(percentage of subjects) Headache 21 (14.8 %) Fever 20 (14.1%) Dermatitis 14 (9.9%) Blood Pressure Increased 11 (7.7%) * Any infusional and any study medication related adverse events. Two serious adverse reactions (headache and vomiting) were reported in one subject but did not lead to discontinuation of PANZYGA. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of PANZYGA. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Blood and lymphatic system disorders Leucopenia, hemolysis, pancytopenia Immune system disorders Hypersensitivity (e.g., anaphylaxis), anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, allergic reaction, angioedema, face edema Metabolic and nutritional disorders Fluid overload, (pseudo)hyponatremia Psychiatric disorders Agitation, confusional state, anxiety, nervousness Nervous system disorders Coma, loss of consciousness, seizures, (acute) encephalopathy, cerebrovascular accident, stroke, aseptic meningitis, migraine, speech disorder, paraesthesia, hypoesthesia, photophobia, tremor Cardiac disorders Myocardial infarction, cardiac arrest, angina pectoris, tachycardia, bradycardia, palpitations, cyanosis Vascular disorders Hypotension, (deep vein) thrombosis, peripheral circulatory failure/collapse, hypertension, phlebitis, pallor Respiratory, thoracic and mediastinal disorders Apnea, Acute Respiratory Distress Syndrome (ARDS), TRALI, respiratory failure, pulmonary embolism, pulmonary edema, bronchospasm, dyspnea, hypoxia, wheezing, cough Gastrointestinal disorders Diarrhea, hepatic dysfunction, abdominal discomfort Skin and subcutaneous tissue disorders Eczema, urticaria, rash (erythematous), pruritus, alopecia, Stevens-Johnson syndrome, epidermolysis, skin exfoliation, erythema (multiforme), dermatitis (e.g., bullous dermatitis) Musculoskeletal and connective tissue disorders Back pain, arthralgia, myalgia, musculoskeletal pain, muscle stiffness, pain in extremity, neck pain, muscle spasm Renal and urinary disorders Acute renal failure, osmotic nephropathy, renal pain General disorders and administration site conditions Injection site reaction, chills, chest pain or discomfort, hot flush, flushing, flu-like illness, feeling cold or hot, edema, hyperhidrosis, malaise, asthenia, lethargy, burning sensation Investigations Hepatic enzymes increased, oxygen saturation decreased, falsely elevated erythrocyte sedimentation rate, positive direct antiglobulin (Coombs’) test
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Adverse Reaction</content></td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> No. of Subjects with Adverse Reaction(percentage of subjects)</content></td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Headache</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 11 (22%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Abdominal pain (upper)</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 7 (14%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Fever</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 7 (14%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Nausea</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 5 (10%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Sinusitis</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 4 (8%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Fatigue</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 3 (6%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Bronchitis</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 3 (6%)</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Adverse Reaction</content></td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> No. of Subjects with Adverse Reaction(percentage of subjects)</content> <content styleCode="bold"/></td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Headache</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 20 (50%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Fever</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 9 (23%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Nausea</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 7 (18%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Vomiting</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 4 (10%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Dizziness</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 4 (10%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Anemia</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 4(10%)</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Adverse Reaction</content></td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> No. of Subjects with Adverse Reaction(percentage of subjects)</content></td></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Headache</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 21 (14.8 %)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Fever</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 20 (14.1%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Dermatitis</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 14 (9.9%)</td></tr><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"> Blood Pressure Increased</td><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"> 11 (7.7%)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.